GRNA News and Press, GreenLight Biosciences Holdings PBC From 04/12/23

BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today released its inaugural Sustainability Re...

2023-03-30 16:55:04 ET GreenLight Biosciences ( NASDAQ: GRNA ) is up ~10% in after-hours trading after confirming that a private equity fund is interested in the company. The RNA biotech company said it received a non-binding indication of interest from Fall Line Endur...

BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA) (“GreenLight” or the “Company”), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and a...

2023-03-28 17:14:42 ET GreenLight Biosciences press release ( NASDAQ: GRNA ): Q4 GAAP EPS of -$0.26 beats by $0.03 . Revenue of $3.02M (+619.0% Y/Y) beats by $1.42M . Cash, cash equivalents, and marketable securities were $68.1 million as of December 31, 2022, ...

Two agriculture solutions now under regulatory review, pending EPA approval: Calantha™, a solution to protect potatoes, and a separate solution to protect honeybees from Varroa mite Updated clinical strategy to accelerate development of its next-generation Covid vaccine candida...

-- Progressing human health pipeline conferring mRNA platform advantages for infectious disease and personalized oncology medicines; pursuing capital efficient strategy targeting unmet medical needs, in both the developed and lower- and middle-income countries (LMICs), pairing focused R&D spe...

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, will today outline its pipeline strategy and R&a...

BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today announced it will host a two-part R&D ...

The Rwanda FDA has given regulatory approval to GreenLight to start a Phase I/II clinical trial of its Covid-19 vaccine candidate in Rwanda. This phase I/II clinical trial is the first step in GreenLight’s integrated strategy of bringing a universal Covid-19 mRNA vaccine to market glob...

The effort will combine GreenLight’s mRNA design and manufacturing expertise with EpiVax’s advanced Ancer® pipeline for personalized cancer vaccine design Epivax Therapeutics, Inc. will contribute a proprietary set of immunoinformatics tools for rapidly identifying and diff...